As other vaccine competitors like Moderna Inc and AstraZenecaalso make significant progress, Pfizer and BioNTech said they had started "rolling" applications in Europe and the UK.
It comes as Pfizer/BioNTech made an emergency request to USA regulators seeking authorisation to begin distributing millions of doses of its BNT162b2 vaccine to high-risk populations.
"We were pleased to see that our vaccine was not only well tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers".
As per a press release on the early results, the vaccine was tested in 560 adults who received two doses of the vaccine or a placebo vaccine.
Oxford University and AstraZeneca Plc's Covid-19 antibody shot has created a "powerful immune reaction" in older candidates over 60 years old and is secure, as indicated by another study from mid-stage trials uncovered this Wednesday.
Pfizer said its Phase 3 trial results were found to be 95 per cent effective and the company plans to seek emergency use authorization from US regulators in the coming days. Data released in July showed the vaccine generated robust immune responses in adults aged 18 to 55.
BBC names retired judge to lead investigation into 1995 Princess Diana interview
These bank statements were allegedly used as proof that someone was leaking information about their family in exchange for money. Diana also questioned Charles's suitability as king.
Besides, the cold storage requirements also pose a challenge for developing countries like India in the procurement of the vaccines.
The Government has placed orders for 100 million doses of the vaccine (enough to vaccinate most of the population) should it receive regulatory approval.
Sinopharm is testing two vaccines in late-stage trials in countries including the UAE, Bahrain, Egypt, Jordan, Peru, and Argentina.
Older adults have an increased risk of COVID-19, so it's crucial that vaccines against the disease are effective in this age group.
Another possible vaccine candidate: Moderna, another pharmaceutical company, announced Monday that early results from its clinical trials show their vaccine is 94.5% effective.
Thirteen serious adverse events occurred in the six months since the first dose was given, none of which were related to either study vaccine.